Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver iron accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus. Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular iron export and iron binding to transferrin. RESULTS: A novel homozygous ceruloplasmin gene mutation, c.2554+1G>T, was identified as the cause of aceruloplasminemia in three affected siblings. Two siblings presented with movement disorders and diabetes. Complementary DNA sequencing showed that this mutation causes skipping of exon 14 and deletion of amino acids 809-852 while preserving the open reading frame. Western blotting of liver extracts and sera of affected patients showed retention of the abnormal protein in the liver. Aceruloplasminemia was associated with severe brain and liver iron overload, where hepatic mRNA expression of the iron hormone hepcidin was increased, corresponding to the degree of iron overload. Hepatic iron concentration normalized after 3 and 5months of iron chelation therapy with deferasirox, which was also associated with reduced insulin demands. During short term treatment there was no clinical or imaging evidence for significant effects on brain iron overload. CONCLUSIONS: Aceruloplasminemia can show an incomplete clinical penetrance but is invariably associated with iron accumulation in the liver and in the brain. Iron accumulation in aceruloplasminemia is a result of defective cellular iron export, where hepcidin regulation is appropriate for the degree of iron overload. Iron chelation with deferasirox was effective in mobilizing hepatic iron but has no effect on brain iron.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 1×
“This results in cellular iron retention and reduced iron absorption [28,29].”
Oxidative stress and neurodegeneration: where are we now?
Halliwell, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03907.x · Cited by 2,614 · cited 1×
“Journal of Hepatology 20 Iron-mediated lipid peroxidation and oxidative stress are the main causes of neurodegeneration secondary to brain iron accumulation [33,34].”
Hereditary Hemochromatosis — A New Look at an Old Disease
Pietrangelo, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031573 · Cited by 992
Regulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756 · cited 1×
“This results in cellular iron retention and reduced iron absorption [28,29].”
Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux
Harris, Z. L., Durley, A. P., Man, T. K., & Gitlin, J. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.19.10812 · Cited by 568 · cited 1×
“CP is a multi-copper ferroxidase essential for iron homeostasis which facilitates cellular iron efflux [7,24].”
A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans
Yoshida, K., Furihata, K., Takeda, S., Nakamura, A., Yamamoto, K., Morita, H., Hiyamuta, S., Ikeda, S.-I., Shimizu, N., & Yanagisawa, N. (1995) · Nature Genetics · doi:10.1038/ng0395-267 · Cited by 463 · cited 1×
“The phenotypic similarity with CP nonsense mutations further suggests that this variant is dysfunctional [32].”
De Domenico, I., Ward, D. M., di Patti, M. C. B., Jeong, S. Y., David, S., Musci, G., & Kaplan, J. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601735 · Cited by 350 · cited 3×
“Ferroxidase activity is required to stabilize the iron export pump ferroportin in cells expressing GPIanchored CP, which provides a molecular explanation for cellular iron retention in ACP [9].”
InfluentialPatel, B. N., Dunn, R. J., & David, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.4305 · Cited by 202 · cited 3×
“Skipping of exon 14 is also predicted to affect the alternative transcript in the brain, where activation of a cryptic splice-site results in direct splicing of exons 18–20 [6].”
InfluentialUse of desferrioxamine in the treatment of aceruloplasminemia
Miyajima, H., Takahashi, Y., Kamata, T., Shimizu, H., Sakai, N., & Gitlin, J. D. (1997) · Annals of Neurology · doi:10.1002/ana.410410318 · Cited by 173
Aceruloplasminemia: An Inherited Neurodegenerative Disease with Impairment of Iron Homeostasis
XU, X., PIN, S., GATHINJI, M., FUCHS, R., & HARRIS, Z. L. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.024 · Cited by 160
Cited by
Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms
Levi, S., & Finazzi, D. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00099 · Cited by 164
Iron and innate antimicrobial immunity-depriving the pathogen, defending the host
Nairz, M., Dichtl, S., Schroll, A., Haschka, D., Tymoszuk, P., Theurl, I., & Weiss, G. (2018) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2018.03.007 · Cited by 123
Levi, S., & Tiranti, V. (2019) · Pharmaceuticals · doi:10.3390/ph12010027 · Cited by 90
“results obtained in mice, iron chelation therapy in patients was disappointing since it only partially reduced systemic iron deposition in liver and pancreas [25], but it was ineffective in reducing the brain iron accumulation and thus in controlling neurodegeneration [12,26].”
ResultIron chelation and multiple sclerosis
Weigel, K. J., Lynch, S. G., & LeVine, S. M. (2014) · ASN NEURO · doi:10.1042/an20130037 · Cited by 63
“In three patients with aceruloplasminemia, deferasirox (start dose of 17–20 mg/kg per day; the dose was reduced or stopped at different times for each patient with treatment lasting 1 week to 5 months) was found to improve liver iron accumulation but did not lessen iron accumulation in the brain (Finkenstedt et al., 2…”
BackgroundHow I manage patients with atypical microcytic anaemia
Camaschella, C. (2013) · British Journal of Haematology · doi:10.1111/bjh.12081 · Cited by 49
Metadata
- Authors
- Finkenstedt, A., Wolf, E., Höfner, E., Gasser, B. I., Bösch, S., Bakry, R., Creus, M., Kremser, C., Schocke, M., Theurl, M., Moser, P., Schranz, M., Bonn, G., Poewe, W., Vogel, W., Janecke, A. R., & Zoller, H.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 53
- Issue
- 6
- Pages
- 1101-1107
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2170854462
- Cited by
- 88
- References
- 10
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.